Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients

Summary

The purpose of this trial is to assess the efficacy and tolerability of memantine (anti-excitotoxic, neuroprotective treatment currently used in Alzheimer's disease \[AD\]) in frontotemporal dementia patients after a one-year treatment.

Timeline

Start

2005-09

Primary completion

—

Completion

—

Outcome

Missed primary endpoint

paper there were no significant differences between the memantine group (n = 23) and the placebo group (n = 26); p = 0.4458; PMID 21157021 ↗

Publications

• Results Vercelletto M, Boutoleau-Bretonniere C, Volteau C, Puel M, Auriacombe S, Sarazin M, Michel BF, Couratier P, Thomas-Anterion C, Verpillat P, Gabelle A, Golfier V, Cerato E, Lacomblez L; French research network on Frontotemporal dementia. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimers Dis. 2011;23(4):749-59. doi: 10.3233/JAD-2010-101632.
• Boutoleau-Bretonniere C, Lebouvier T, Volteau C, Jaulin P, Lacomblez L, Damier P, Thomas-Anterion C, Vercelletto M. Prospective evaluation of behavioral scales in the behavioral variant of frontotemporal dementia. Dement Geriatr Cogn Disord. 2012;34(2):75-82. doi: 10.1159/000341784. Epub 2012 Aug 23.

Drugs

Indications